INTRODUCTION
Adalimumab (HUMIRA Ò , AbbVie, North Chicago, IL) is an anti-tumor necrosis factor (TNF) agent indicated for the treatment of 15 conditions, including adult and pediatric plaque psoriasis (Ps), hidradenitis suppurativa (HS), rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), nonradiographic axial spondyloarthritis (nr-axSpA), polyarticular juvenile idiopathic arthritis (pJIA), enthesitis-related arthritis, adult and pediatric Crohn's disease (CD), ulcerative colitis (UC), adult and pediatric uveitis (UV), and Behçet's disease [1, 2] .
The long-term safety of adalimumab was previously reported in 23,458 patients representing up to 12 years of clinical trial exposure [3] . Infections were the most frequently reported serious events, ranging from 1.4/100 patientyears (PY) to 6.7/100 PY across indications [3] . Non-melanoma skin cancer (NMSC) incidence rates were higher in Ps, RA, and CD compared with 10-year age-specific incidence rates in the USA from 1977 to 1978, but the overall malignancy rates (excluding NMSC) were as expected for the general population. Death rates were lower or equivalent to rates expected for the general population. The safety profile of adalimumab was also consistent with that of anti-TNF agents in real-world registries [4] [5] [6] [7] .
Since the previous analysis, adalimumab has been approved for new indications (e.g., HS and UV) and additional clinical trial data across indications have become available [1, 2] . The objective of this updated analysis was to examine the safety of adalimumab in adult patients with Ps, HS, RA, AS, nr-axSpA, peripheral SpA (pSpA), PsA, CD, UC, and UV, with a special focus on mortality rates with extended adalimumab treatment.
METHODS

Clinical Trials
Safety data from 77 clinical trials of adalimumab (33 RA [77, 78] , 1 pSpA [79] ) were included from randomized controlled, open-label, and longterm extension studies conducted through December 31, 2016. Adalimumab postmarketing surveillance data were not included in this analysis because of limitations associated with voluntary reporting. Of note, this analysis did not include pediatric patients; a separate analysis on pediatric safety was recently published [80] .
The studies were conducted in accordance with the International Conference on Harmonisation Good Clinical Practice guidelines and the Declaration of Helsinki, and were approved by institutional review boards and/or independent ethics committees according to local law. All patients provided informed consent before any study procedures were conducted.
Safety Assessments
Safety assessments included all treatment-emergent adverse events (AEs) and serious AEs (SAEs) that occurred after the first adalimumab study dose and within 70 days (5 half-lives) after the last study dose. Events that were fatal or life threatening, required in-patient or prolonged hospitalization, resulted in persistent or significant disability/incapacity or congenital anomaly, required medical or surgical intervention to prevent a serious outcome, or other medically important conditions (e.g., miscarriage/spontaneous abortion, elective abortion) were categorized as SAEs. AEs were coded using the Medical Dictionary for Regulatory Activities version 19.1 preferred terms (https://www.meddra.org/). SAEs of interest included infections (including opportunistic infections and tuberculosis [TB]), demyelinating disorder, lupus-like syndrome, congestive heart failure (CHF), new onset or worsening of psoriasis, malignancy (including lymphoma, non-melanoma skin cancer [NMSC], and melanoma), and sarcoidosis. Rates are reported as events per 100 PY. Kaplan-Meier analyses were used to evaluate the time to first serious infection event and the time to first malignancy (excluding lymphoma, hepatosplenic T-cell lymphoma, leukemia, NMSC, and melanoma).
Standardized incidence rates (SIRs) were calculated as the ratio of observed to expected number of malignancies; 95% CIs for SIRs were calculated assuming that observed malignancies followed a Poisson distribution. To correspond with previously conducted SIR analyses of longterm adalimumab safety data, the data from the ReAlise uncontrolled observational study of patients with RA [23] were not included. The expected numbers of malignancies, excluding NMSC, for SIR calculations were based on 5-year, age-specific incidence rates from the National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) database, 2000-2007 (http://www.seer.cancer.gov). No similar database is available for Europe, Australia, or Canada, so an assumption was made that patients from these regions could be pooled with those from the USA. Because the NCI SEER database does not include NMSC, NMSC rates were based on age-specific incidence rates from an NCI survey in the USA from 1977 to 1978 [81] .
Standardized mortality rates (SMR) were calculated as the ratio of observed deaths to expected deaths estimated on the basis of country-specific, baseline age-and sex-matched population data from the World Health Organization for 1997-2006 (https://www.who.int/ gho/publications/world_health_statistics/whostat 2006_erratareduce.pdf). The confidence interval of the SMR was calculated with a formula from Breslow and Day that uses Byar's approximation [82] .
RESULTS
This analysis included 29,967 patients representing 56,916 PY of exposure. Baseline characteristics are summarized in Table 1 . The highest adalimumab exposure was in the RA studies (37,106 PY), followed by Ps (5479 PY). Overall, 9355 patients had more than 2 years of exposure and 4003 patients had more than 5 years of exposure.
A total of 3867 (12.9%) patients discontinued because of a treatment-emergent AE (8.7/ 100 PY). The most common AEs leading to discontinuation in the total population were Crohn's disease (0.4/100 PY), rheumatoid arthritis (0.3/100 PY), ulcerative colitis (0.3/ 100 PY), and pneumonia (0.2/100 PY); all other events were reported with a rate of at most 
Any AE leading to death 0.6 0. (Fig. 1) .
The overall rate of serious TB was 0.2/100 PY ( Table 2 ). The highest rate of serious active TB was observed among patients with Ps, RA, PsA, and UV. No cases of active TB were seen in patients with HS or pSpA, and no cases of latent TB were seen among patients with Ps, HS, AS, nr-axSpA, PsA, or UC; however, testing for latent TB was not performed in most trials after treatment was started.
The overall rate of serious opportunistic infections, excluding TB and oral candidiasis, was less than 0.1/100 PY (27 events), with the highest rate reported in UV studies (0.4/100 PY; 5 events); the rate of opportunistic infections did not exceed 0.1/100 PY in other indications ( Table 2 ). The most common serious opportunistic infection was esophageal candidiasis (\ 0.1/100 PY; 4 events); no other event occurred more than twice. No serious opportunistic infections were reported in Ps, HS, AS, pSpA, and PsA studies ( Table 2) , and no events of serious oral candidiasis were reported in any of the studies. The rates of serious demyelinating disorders, lupus-like syndrome, and new onset/worsening of psoriasis and sarcoidosis across all indications were at most 0.1/100 PY. With the exception of UV (0.3/100 PY; 3 events), the rate of demyelinating disorders did not exceed 0.1/100 PY across individual indications (25 events across all indications; Table 2 ). The overall rate of serious CHF was 0.2/100 PY (97 events), with the highest rate (0.2/100 PY) occurring in patients with HS and RA ( Table 2) . No cases of progressive multifocal leukoencephalopathy were reported in these adalimumab clinical trials.
The overall rate of serious malignancies, excluding serious lymphoma, hepatosplenic T-cell lymphoma, leukemia, NMSC, and melanoma, was 0.6/100 PY across indications (ranging from 0.1 to 0.7/100 PY), with the highest rates reported among RA, UV, and UC studies ( Table 2) . The time to first malignancy, excluding lymphoma, hepatosplenic T-cell lymphoma, leukemia, NMSC, and melanoma, was similar between indications ( Fig. 1) . The SIR for all malignancies (excluding NMSC) was based on 321 observed events and was similar to the age-specific incidence rates (Fig. 2) . The observed numbers of malignancies for most individual adalimumab populations (RA, Ps, AS, nr-axSpA, pSpA, and PsA) were below the agespecific rates. The SIR for lymphomas was based on 44 events (with 33 events in the RA population); the number of lymphomas observed across indications and in the RA studies were significantly greater than expected for agespecific incidence rates (Fig. 2) . The SIR for NMSC was based on 280 events (with 191 basal cell carcinoma, 79 squamous cell carcinoma, and 10 unclassified), and the number of events across indications and in the RA, Ps, and CD studies was significantly greater than expected for age-specific incidence rates ( Fig. 2) . Although the SIR for NMSC was higher for HS and UV compared with Ps, RA, and CD, it was not significantly different from expected agespecific incidence rates in these two populations. The SIR for melanomas was based on 24 events (RA, 14 events; Ps, 6 events; UC, 3 events; AS, 1 event). In patients with Ps, the SIR for melanoma was significantly higher compared with age-specific incidence rate.
Overall, 232 deaths were recorded. Deaths were reported in each indication, with the highest rates among RA and UV studies (0.6/ 100 PY). For most of the adalimumab populations (Ps, RA, AS, PsA, UC, and CD), the observed number of deaths was below what would be expected in an age-and sex-adjusted general population ( Fig. 3 ). For HS, nr-axSpA, pSpA, and UV studies, the small size of these trials precluded accurate assessment of the standardized mortality ratio, and the 95% CIs all included 1.0.
DISCUSSION
This analysis of 29,967 adult patients, representing 10 indications and 56,916 PY of adalimumab exposure, is the most comprehensive safety analysis of adalimumab clinical trials reported to date. These results add to the previous safety analyses [3, 83] and the pediatric safety analysis [80] and demonstrate that no new safety findings were noted with increasing adalimumab exposure. Rates of SAEs of interest remained low and consistent with those reported for TNF inhibitors [4] [5] [6] [7] .
Infections remained the most commonly reported SAE across indications [3] . The overall rate of serious infections was 3.7/100 PY and ranged from 1.0 to 6.9/100 PY across indications, with the highest rates reported among patients with CD, UV, RA, and UC and lowest among patients with pSpA, psoriasis, and AS. These are similar to serious infection rates reported for adalimumab in real-world registries [84] [85] [86] as well as for those reported for other TNF inhibitors [5-7, 84, 87, 88] . The higher rates of infections among patients with CD, RA, UV, and UC may be associated with concomitant corticosteroid use, which was highest among these patient populations, and patient characteristics, such as age and disease duration [6, 7, 89, 90] . For example, for CD and UC, an increased rate of infection may occur early in the course of treatment, while in severe disease, infection may be related to the underlying disease, independent of treatment.
Opportunistic infections are possible with TNF inhibitor therapy as a result of their immunosuppressive nature [91] . Our long-term analysis demonstrated that the overall rates of serious opportunistic infections (excluding tuberculosis and oral candidiasis) and serious active tuberculosis were low. With the exception of UV, the rates of serious opportunistic infections were at most 0.1/100 PY across indications. The highest rate of serious active TB was found among patients with Ps, RA, PsA, and UV. The rates of serious opportunistic infections and active TBs were similar to the previous analysis [3] and were consistent with rates reported for adalimumab and other TNF inhibitors in clinical and real-world registry studies [86, [92] [93] [94] [95] [96] .
The rates of other SAEs of interest were low. The overall rates of serious demyelinating disorders, lupus-like syndrome, and sarcoidosis were less than 0.1/100 PY. The overall rate of serious CHF was 0.2/100 PY, with the highest rates observed in HS and RA. This is noteworthy considering that patients with Ps have increased incidence and prevalence of cardiovascular risk factors [97] . However, the risk of cardiovascular events was also low with TNF inhibitor therapy in real-world registries of Ps [4, 86] and RA [5, 98] . Furthermore, recent studies have suggested decreased risk of cardiovascular events with TNF inhibitor therapy in patients with Ps, RA, and PsA [99, 100] . Future studies are needed to confirm these results.
The SIR for all malignancies (excluding NMSC) was similar to the age-specific incidence rates and the observed numbers of malignancies for most individual adalimumab populations (RA, Ps, AS, PsA, nr-axSpA, and pSpA) were below the age-specific rates. Overall, the rate of serious malignancies was generally similar to that reported for TNF inhibitors in real-world Ps and RA registries [4, [101] [102] [103] . The time to onset of a first malignant event was stable across indications, suggesting no increased risk over time with prolonged treatment. However, the SIRs for lymphoma and NMSC in patients with RA were higher than those observed in agematched populations. In addition, increased incidences of NMSC were observed in patients with Ps and CD compared with age-matched populations. These findings were not entirely unexpected because increased risk of lymphoma and/or NMSC has been reported in patients with Ps, RA, and CD [104] [105] [106] [107] [108] . Furthermore, elevated rates of lymphoma and NMSC have been reported in patients with CD and RA receiving TNF inhibitors [103, 105, 109, 110] . However, TNF inhibitor treatment did not significantly increase the risk of lymphoma or NMSC in two other studies in patients with RA [108, 111] . Similar observations were reported in a Swedish registry analysis among patients with AS and PsA [112] .
The risk of mortality was not increased in adalimumab-treated patients compared with the general population, and for most patients (including Ps) the observed number of deaths was below what would be expected in an ageand sex-adjusted population. There are a few possibilities to explain these interesting findings. First, the so-called healthy-cohort effect resulting from tighter monitoring and possible lifestyle changes (less smoking, healthier diet, more exercise) of patients in clinical trials may affect mortality. Second, the reduction in inflammation observed with anti-cytokine treatment may lead to fewer cardiovascular events and thus lowered mortality rate [113, 114] , and decreased risk of cardiovascular events with TNF inhibitor therapy reported in patients with Ps, RA, and PsA [99, 100] . However, it may also be possible that the improved life expectancy results from the rigorous screening (and exclusion criteria) before entering the trial and then the careful medical care that follows.
Limitations of this analysis of randomized clinical studies included the lack of real-life data and limited long-term data ([ 5 years) for most patients. Nevertheless, this is a comprehensive long-term safety analysis of adalimumab studies that included 9355 patients with more than 2 years of exposure (compared with 5209 patients in the previous analysis) and 4003 patients with more than 5 years of exposure (compared with 1971 patients in the previous analysis) [3] . Other strengths of this analysis included rigorous safety monitoring in the clinical trials, reporting for several indications, and robust mortality data.
CONCLUSIONS
Taken together, this analysis of adalimumab trials with 56,916 PY of exposure demonstrated an overall safety profile consistent with previous findings [3, 83, 115, 116] and with other anti-TNF agents [4] [5] [6] [7] . No new safety signals or tolerability issues were identified, and the risk of mortality was not increased compared with the general population.
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